{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T14:29:11Z","timestamp":1788791351402,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,21]]},"DOI":"10.7759\/cureus.69844","type":"journal-article","created":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T12:09:37Z","timestamp":1726920577000},"source":"Crossref","is-referenced-by-count":6,"title":["Acute Pancreatitis Likely Due to Semaglutide"],"prefix":"10.7759","author":[{"given":"Katie","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yovan Ram Kurrun","family":"Sumaruth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmahi","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibhootee","family":"Sant Bakshsingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212585","article-title":"Clinical potential of treatment with semaglutide in type 2 diabetes patients","volume":"8","author":"R\u00f8der ME","year":"2019","unstructured":"R\u00f8der ME. Clinical potential of treatment with semaglutide in type 2 diabetes patients. Drugs Context. 2019, 8:212585. 10.7573\/dic.212585","journal-title":"Drugs Context"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier JJ","year":"2012","unstructured":"Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012, 8:728-42. 10.1038\/nrendo.2012.140","journal-title":"Nat Rev Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker DJ","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018, 27:740-56. 10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dci19-0066","article-title":"2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"Buse JB","year":"2020","unstructured":"Buse JB, Wexler DJ, Tsapas A, et al.. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020, 43:487-93. 10.2337\/dci19-0066","journal-title":"Diabetes Care"},{"key":"ref6","unstructured":"FDA. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. (2021). Accessed: August 26, 2024: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-chronic-weight-management-first-2014."},{"key":"ref7","unstructured":"Weight Loss Drugs Alone Are Not Enough for Individuals to Achieve Health Goals, Researchers Say. (2024). Accessed. August 22, 2024: https:\/\/www.ucl.ac.uk\/news\/2024\/aug\/weight-loss-drugs-alone-are-not-enough-individuals-achieve-health-goals-researche...."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645563","article-title":"Safety of semaglutide","volume":"12","author":"Smits MM","year":"2021","unstructured":"Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol (Lausanne). 2021, 12:645563. 10.3389\/fendo.2021.645563","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0386-8","article-title":"Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies","volume":"48","author":"Giorda CB","year":"2015","unstructured":"Giorda CB, Sacerdote C, Nada E, Marafetti L, Baldi I, Gnavi R. Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. Endocrine. 2015, 48:461-71. 10.1007\/s12020-014-0386-8","journal-title":"Endocrine"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12885","article-title":"Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes","volume":"19","author":"Storgaard H","year":"2017","unstructured":"Storgaard H, Cold F, Gluud LL, Vilsb\u00f8ll T, Knop FK. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab. 2017, 19:906-8. 10.1111\/dom.12885","journal-title":"Diabetes Obes Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/0897190018760645","article-title":"Mirtazapine-induced pancreatitis-a case report","volume":"32","author":"Bowers RD","year":"2019","unstructured":"Bowers RD, Valanejad SM, Holombo AA. Mirtazapine-induced pancreatitis-a case report. J Pharm Pract. 2019, 32:586-8. 10.1177\/0897190018760645","journal-title":"J Pharm Pract"},{"key":"ref12","article-title":"Glucagon-Like Peptide-1 Receptor Agonists","author":"Collins L","year":"2024","unstructured":"Collins L, Costello RA. Glucagon-Like Peptide-1 Receptor Agonists. StatPearls Publishing, Treasure Island, Florida; 2024."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2014.0188","article-title":"Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"17","author":"Sun F","year":"2015","unstructured":"Sun F, Chai S, Yu K, et al.. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Technol Ther. 2015, 17:35-42. 10.1089\/dia.2014.0188","journal-title":"Diabetes Technol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu L","year":"2022","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022, 13:1043789. 10.3389\/fendo.2022.1043789","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4158\/EP11290.OR","article-title":"Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting","volume":"18","author":"Lando HM","year":"2012","unstructured":"Lando HM, Alattar M, Dua AP. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract. 2012, 18:472-7. 10.4158\/EP11290.OR","journal-title":"Endocr Pract"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi M","year":"2023","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. J Am Med Assoc. 2023, 330:1795-7. 10.1001\/jama.2023.19574","journal-title":"J Am Med Assoc"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1686","article-title":"Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors","volume":"62","author":"Butler AE","year":"2013","unstructured":"Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes. 2013, 62:2595-604. 10.2337\/db12-1686","journal-title":"Diabetes"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2023.102834","article-title":"Semaglutide and cancer: a systematic review and meta-analysis","volume":"17","author":"Nagendra L","year":"2023","unstructured":"Nagendra L, Bg H, Sharma M, Dutta D. Semaglutide and cancer: a systematic review and meta-analysis. Diabetes Metab Syndr. 2023, 17:102834. 10.1016\/j.dsx.2023.102834","journal-title":"Diabetes Metab Syndr"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study","volume":"173","author":"Singh S","year":"2013","unstructured":"Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013, 173:534-9. 10.1001\/jamainternmed.2013.2720","journal-title":"JAMA Intern Med"},{"key":"ref20","unstructured":"NICE. Pancreatitis-Acute: What Are the Risk Factors and Causes?. (2021). Accessed: August 19, 2024: https:\/\/cks.nice.org.uk\/topics\/pancreatitis-acute\/background-information\/risk-factors-causes\/."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/295395-acute-pancreatitis-likely-due-to-semaglutide","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T12:09:40Z","timestamp":1726920580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/295395-acute-pancreatitis-likely-due-to-semaglutide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,21]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.69844","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,21]]}}}